These data indicate that: ovarian cancer cell lines are sensitive to LBW242 effects, particularly in combined treatment with TRAIL; LBW242 exerts a synergistic or additive anti-tumor activity with TRAIL in ovarian cancer cell lines. Here, TNFSF10 is linked to ovarian cancer.